Sarcoidosis

Sarcoidosis belongs to the category of systemic granulomatous inflammatory diseases—conditions in which the immune system forms organized clusters of inflammatory cells, called granulomas, inside the body’s tissues. Granulomas are not cancerous tumors and are not caused by infection—they are abnormal collections of immune cells that the body forms when it cannot fully resolve an inflammatory trigger. In most cases, the lungs and lymph nodes are involved, but sarcoidosis is distinctive in that granulomas can form in virtually any organ. Because its symptoms vary so widely depending on where the granulomas develop, sarcoidosis has earned the nickname “the great imitator”—it can resemble many other conditions and frequently goes unrecognized for months or years before a diagnosis is reached.

Sarcoidosis is a multisystem disease of unknown cause in which granulomas infiltrate organs throughout the body. Each granuloma is an organized cluster of macrophage-derived epithelioid cells (transformed immune cells), Langhans giant cells (fused macrophages), and CD4+ T lymphocytes—the immune cells that coordinate the inflammatory response. A defining pathological feature is that sarcoid granulomas are non-necrotizing, meaning they do not have the central zone of tissue death (necrosis) that characterizes the granulomas of tuberculosis and some fungal infections. This distinction is critical for diagnosis. In many patients, the granulomas eventually resolve on their own; in others, they progress to fibrosis—permanent scarring that can impair the function of affected organs. Sarcoidosis is also known historically as Boeck’s sarcoid and Besnier–Boeck–Schaumann disease.

Sarcoidosis is one of the most common interstitial lung diseases worldwide, with a U.S. incidence of 8 to 11 cases per 100,000 persons per year overall—and 17.8 per 100,000 among African Americans, who bear the highest disease burden in the United States. Prevalence in African Americans reaches up to 140 per 100,000 compared to 50 per 100,000 in white Americans, and the lifetime risk of developing sarcoidosis is 2.4% for African Americans versus 0.85% for Caucasian Americans. The disease’s trajectory is highly variable. Approximately 60–66% of patients experience spontaneous remission within 12 to 36 months, often without any treatment. However, roughly 40% develop a chronic course, and 10–30% require prolonged medical management. Mortality is 2–4% in Western countries overall, but substantially higher in African Americans and in Japanese patients with cardiac involvement—reflecting both disease biology and healthcare access disparities. The U.S. age-adjusted sarcoidosis mortality rate rose from 3.9 per 100,000 in 1999 to 6.4 per 100,000 in 2020, with 37,956 sarcoidosis-related deaths documented over that period. In Western countries, advanced pulmonary fibrosis leading to respiratory failure is the leading cause of death; in Japan, cardiac involvement accounts for 77% of sarcoidosis deaths.

Physicians classify sarcoidosis using three parallel frameworks: which organs are involved (the primary clinical framework), which named clinical phenotype the presentation matches (guides prognosis and treatment strategy), and where on the Scadding radiographic scale the pulmonary disease falls (for the large majority of patients with lung involvement).

• Pulmonary sarcoidosis: the most common form; intrathoracic involvement occurs in more than 90% of all sarcoidosis patients. Granulomas form in the lymph nodes at the base of the lungs (the lung roots, or hila), in the lung tissue itself, or both. Respiratory symptoms—persistent dry cough, shortness of breath, and chest tightness—are present in 30–53% of those with lung involvement. In the most advanced cases, progressive pulmonary fibrosis (permanent lung scarring) develops.
• Cutaneous sarcoidosis: Skin is the second or third most commonly affected organ, present in 20–35% of patients. Skin involvement takes two forms. Specific lesions—which contain granulomas on biopsy—include papules, plaques, subcutaneous nodules, and lupus pernio (firm, violaceous, indurated plaques on the nose, cheeks, lips, and earlobes; a marker of chronic, treatment-resistant disease that disproportionately affects African American women). Nonspecific lesions contain no granulomas and are reactive; the most common is erythema nodosum—tender, red-purple bumps typically over the shins, and a marker of acute, self-limiting disease.
• Ocular sarcoidosis: Eye involvement affects 10–50% of patients and is more common in African American patients and women. Uveitis—inflammation of the eye’s middle layer—is the most common ocular manifestation, with anterior uveitis accounting for 41–75% of ocular cases; 75–90% of cases affect both eyes. Sarcoidosis also causes lacrimal gland enlargement (10–69%), conjunctival granulomas (6–40%), and optic neuritis (1–5%).
• Cardiac sarcoidosis: Clinically detected in 20–27% of sarcoidosis patients using advanced imaging, with higher rates found in autopsy studies. Cardiac sarcoidosis is potentially life-threatening, causing ventricular arrhythmias, complete atrioventricular (AV) block, heart failure, and sudden cardiac death. It accounts for approximately 25% of all sarcoidosis deaths. At Montefiore Einstein, 19.1% of a cohort of 220 patients met diagnostic criteria for cardiac sarcoidosis—70% female and 56.4% Black.
• Neurosarcoidosis: Nervous system involvement occurs in 5–20% of patients. The most common manifestation is cranial neuropathy (55%), with the facial nerve and optic nerve most frequently affected. Additional features include headache (32%), peripheral neuropathy and muscle involvement, aseptic meningitis, encephalopathy, seizures, and, in severe cases, spinal cord and pituitary infiltration.
• Hepatic and splenic sarcoidosis: Autopsy studies show liver involvement in up to 80% of sarcoidosis cases, though symptomatic disease occurs in only about 18%. Elevated alkaline phosphatase (a liver enzyme) is common. Portal hypertension—increased pressure in the liver’s blood supply—develops in 3–20% of symptomatic cases. Splenic involvement is detected at similar frequency, and splenomegaly (an enlarged spleen) occurs in up to 6%.
• Musculoskeletal sarcoidosis: Joint involvement (sarcoid arthropathy) affects 6 to 35% of patients, most commonly as bilateral ankle arthritis. Bone involvement occurs in 0.5–30%, depending on sensitivity of imaging; the finger and toe bones are the most common sites. Muscle involvement is very common on biopsy (50–80%), but symptomatic muscle weakness is rare (1.4–2.3%).
• Renal sarcoidosis: Affects approximately 5% of patients. The granulomas’ unregulated production of calcitriol (active vitamin D) causes hypercalciuria (excess calcium in the urine, in 20–40%), kidney stones (10–14%), calcium deposits in the kidney (nephrocalcinosis), interstitial nephritis, and, in severe cases, kidney failure.

• Löfgren syndrome: an acute, clinically distinct, and typically self-limiting presentation: the triad of bilateral hilar lymphadenopathy, erythema nodosum, and bilateral ankle arthritis or periarticular inflammation, with or without fever. It is most common in European Caucasians—accounting for roughly 33% of cases in Sweden and the Netherlands, but only 0.7–0.9% of U.S. cases. Onset peaks between ages 25 and 60, women account for 70%, and 79–82.5% present at Scadding stage I. Chronic disease beyond two years occurs in only 8–22.6% of Löfgren’s syndrome patients. It is strongly associated with the HLA-DRB1*03 genetic marker.
• Heerfordt’s syndrome (uveoparotid fever): a highly specific sarcoidosis subtype characterized by the combination of facial nerve palsy, parotid gland enlargement, uveitis, and low-grade fever. The complete form (all three features) occurs in 0.3% of sarcoidosis patients; an incomplete form (two of three features) in 1.3%.
• Chronic multisystem sarcoidosis: associated with lupus pernio, chronic uveitis, sinonasal and bone involvement, central nervous system and cardiac disease, severe hypercalcemia, and Scadding stages III to IV. African American and Afro-Caribbean ethnicity and age over 40 at presentation are the primary demographic markers. All of these features predict a more difficult and prolonged disease course.

Pulmonary sarcoidosis is classified by the Scadding system based on chest X-ray appearance. Stage 0 shows no visible findings on X-ray. Stage I shows enlarged lymph nodes at the lung roots (bilateral hilar lymphadenopathy) without visible lung tissue changes; spontaneous remission occurs in 55–90% of stage I patients. Stage II adds parenchymal infiltration to the enlarged hilar lymph nodes; remission occurs in 40–70%. Stage III shows parenchymal infiltration without the enlarged hilar nodes; only 10–20% remit spontaneously. Stage IV is advanced fibrosis with permanent architectural changes to the lung—honeycombing, bronchiectasis (irreversibly dilated airways), and bullae; minimal spontaneous remission occurs at this stage.

The exact cause of sarcoidosis remains unknown. Current evidence supports a two-hit model: genetic susceptibility in the host combined with one or more environmental or infectious triggers produces a dysregulated immune response that drives granuloma formation. Neither factor alone appears sufficient—sarcoidosis requires both a susceptible immune system and an external trigger to initiate.

Eleven sarcoidosis risk locations in the human genome have been identified through genome-wide association studies. The most important are BTNL2 (the top non-HLA susceptibility gene), multiple HLA alleles (HLA-B, HLA-DPB1), ANXA11, and IL23R. The HLA alleles are particularly significant because they shape the protein groove through which the immune system’s antigen-presenting cells show foreign (and in this case, possibly self) antigens to T-cells—determining whether a given antigen provokes an immune response. HLA-DRB1*03/DQB1*02 alleles are the most strongly associated with susceptibility and specifically with Lofgren’s syndrome. Tumor necrosis factor (TNF)-alpha and transforming growth factor beta (TGF)-beta gene variants influence granuloma formation and the tendency toward fibrosis, respectively. The genetic contribution to sarcoidosis is substantial: first-degree relatives of sarcoidosis patients have 3.7 times the average risk, identical twins carry an 80-fold elevated risk compared to the general population versus a seven-fold elevation in fraternal twins, and heritability is estimated at 39%. Familial sarcoidosis is reported in 17% of African Americans with the disease.

Sarcoidosis is believed to be triggered when a susceptible individual’s immune system encounters an antigen—a foreign substance—that it cannot properly clear. Inhaled particulates and occupational exposures are the best-documented triggers. Crystalline silica dust carries a standardized incidence ratio of 3.94 in high-exposure construction workers. World Trade Center rescue and recovery workers exposed to building debris had a 2.8-fold elevated sarcoidosis incidence. Agricultural workers, firefighters, and those exposed to metal dust, bioaerosols, organic dusts, and wood stoves all face elevated risk. Mycobacterium tuberculosis (TB) is the strongest infectious candidate—mycobacterial deoxyribonucleic acid (DNA) sequences from TB-specific proteins (ESAT-6, KatG, and SoDA) have been isolated from sarcoidosis tissue specimens. Propionibacterium acnes has been consistently identified in Japanese sarcoidosis tissue. Other candidate organisms include Borrelia burgdorferi, Chlamydia pneumoniae, Mycoplasma species, and several viruses, though none has been definitively proven as a causative agent. Notably, interferon-alpha therapy used for hepatitis C has been documented to trigger sarcoidosis, providing one of the clearest examples of a medication inducing the condition.

Once a triggering antigen enters the lung, it is engulfed by antigen-presenting cells—primarily alveolar macrophages and dendritic cells—that cannot fully degrade it. These cells release TNF-alpha and other cytokines (including IL-12, IL-15, and IL-18) to recruit additional immune cells. They present fragments of the antigen to CD4+ T-cells, which then differentiate into Th1, Th2, or Th17 subsets. The Th1 response is the resolution pathway: if the Th1 cells are able to eliminate the antigen, the granuloma regresses and the patient recovers. The Th2 shift is the fibrotic pathway: when Th2 cells predominate, they stimulate fibroblasts and collagen production, leading to irreversible scarring. The granuloma itself is maintained by TNF-alpha—which is why anti-TNF drugs are effective treatment for refractory sarcoidosis. A critically important biochemical consequence occurs inside active granulomas: macrophages express an enzyme called 1-alpha-hydroxylase that converts vitamin D into its active form (calcitriol) in an unregulated way, independent of the kidney’s normal calcium feedback control. This uncontrolled calcitriol production causes elevated blood calcium (hypercalcemia) and elevated urine calcium (hypercalciuria)—the metabolic signature of active sarcoidosis and the source of kidney stones and calcium deposits in the kidney. When Treg (regulatory T-cells) dysfunction allows the immune cycle to continue unchecked, and when the NLRP3 inflammasome is activated by persistent antigen, the result is the chronic, treatment-resistant form of the disease.

• Race and ethnicity: African Americans and Afro-Caribbeans have the highest incidence, prevalence, and mortality from sarcoidosis of any U.S. population. The incidence rate in African Americans (17.8 per 100,000) is more than double that of white Americans (8.1 per 100,000), and the mortality disparity is dramatic: the death rate in Black Americans is 16 per 100,000 versus 1.3 per 100,000 in white Americans. Scandinavian ancestry carries among the highest global disease rates outside African populations.
• Genetic predisposition: Having a first-degree relative with sarcoidosis increases risk 3.7-fold. Among siblings of affected individuals, the ACCESS study found a fivefold elevated risk. Identical twins carry an 80-fold elevated risk compared to the general population.
• Sex: Women account for a slight overall majority of sarcoidosis cases (45–63% depending on the study). Women are typically diagnosed 5 to 10 years later than men, and women have higher mortality rates in some studies despite similar or lower incidence.
• Age: The peak onset is between 30 and 55 years overall; men peak between 42 and 47 years, women between 48 and 55 years. A second peak in women occurs after age 50, possibly related to hormonal changes following menopause.

• Obesity: the strongest consistently replicated modifiable risk factor. Multiple large cohort studies document hazard ratios of 1.42 (Black Women’s Health Study, n=59,000), 1.74 (Nurses’ Health Study II, n=116,000), and up to 3.59 (Danish National Birth Cohort, n=75,000) for obese individuals compared to normal-weight individuals. The proposed mechanism is that adipose tissue creates a pro-inflammatory environment that shifts alveolar macrophages toward a more reactive phenotype.
• Occupational exposures: Silica dust exposure (standardized incidence ratio 3.94 in high-exposure Swedish construction workers), World Trade Center debris exposure in firefighters and rescue workers (2.8-fold risk), agricultural work with exposure to insecticides, herbicides, and farm bioaerosols, and metal or construction work are all associated with elevated sarcoidosis risk.
• Neighborhood deprivation: High levels of neighborhood deprivation—measured by income, educational attainment, and unemployment rates—are associated with a 20% increased odds of sarcoidosis in Swedish population data, suggesting that social determinants of health contribute to disease burden.

Smoking is paradoxically protective against sarcoidosis development—even smokers had 35% reduced odds in the ACCESS study, and current smokers show an odds ratio of approximately 0.34 versus never smokers. The hypothesized mechanism is nicotine’s immunomodulatory suppression of granulomatous inflammation. This is an unusual statistical finding, not a clinical recommendation: smoking causes vastly greater harm to overall health than any theoretical sarcoidosis protection could offset, and it is not a prevention strategy. However, it does mean that sarcoidosis is more prevalent in never-smokers and that smoking history should be factored into clinical interpretation.

There is no population-level sarcoidosis screening program. The disease is typically identified in one of two ways: incidental discovery on chest imaging obtained for another reason (now accounting for approximately 8.4% of new diagnoses, as routine chest X-rays are less commonly performed than historically), or clinical evaluation prompted by characteristic symptoms. When sarcoidosis is clinically suspected, the following stepwise evaluation applies—it is important to understand that no single gold-standard diagnostic test exists. Diagnosis is always the result of combining clinical, laboratory, imaging, and often histological findings.

Chest X-ray is the first-line imaging test, assigning a Scadding stage and identifying the bilateral hilar lymphadenopathy that is the most characteristic sarcoidosis finding. High-resolution computed tomography (CT) of the chest is used when the X-ray is equivocal or when more detailed characterization is needed. Serum angiotensin-converting enzyme (SACE) is elevated in approximately 60% of active sarcoidosis cases and reflects total granuloma burden—it is useful for monitoring disease activity but lacks the specificity needed as a primary diagnostic test. Pulmonary function tests (spirometry plus diffusing capacity for carbon monoxide—DLCO, which measures the lungs’ ability to transfer gas) establish a functional baseline; a restrictive pattern with reduced DLCO is characteristic, and a composite physiologic index above 40 predicts mortality risk. Serum calcium and 24-hour urine calcium screen for the metabolic consequences of ectopic calcitriol production.

Three organ-specific screening measures apply to all patients newly diagnosed with sarcoidosis, regardless of whether organ symptoms are present. An ophthalmologic slit-lamp examination is recommended for every newly diagnosed patient because sarcoid uveitis is frequently clinically silent yet can cause vision loss if untreated. A baseline electrocardiogram (ECG) is performed to screen for arrhythmias and AV block—markers of cardiac involvement. Liver function tests, including alkaline phosphatase, are obtained as a baseline. For any patient with symptoms suggesting cardiac sarcoidosis (palpitations, syncope, or breathlessness out of proportion to known pulmonary disease), cardiac magnetic resonance imaging (MRI) or 18F-FDG positron emission tomography-computed tomography (PET-CT) is recommended. For any neurological symptoms, an MRI of the brain and spine is performed. Firefighters, mine workers, silica-exposed construction workers, and agricultural workers should have a lower threshold for a sarcoidosis workup when respiratory symptoms or relevant chest X-ray findings develop.

Sarcoidosis cannot be prevented. No vaccine exists, and the specific antigen or antigens triggering the disease have not been definitively identified. The following steps may reduce individual risk or prevent progression to organ damage:

• Weight management: Given the robust obesity-sarcoidosis association across multiple large cohort studies (hazard ratios up to 3.59), maintaining a healthy body mass index (BMI) is the single most modifiable individual risk-reduction strategy.
• Occupational respiratory protection: N95 respirators and engineering controls for silica-exposed workers, firefighters, and agricultural workers reduce inhalation of the particulates most consistently associated with sarcoidosis risk.
• Avoidance of environmental triggers for high-risk individuals: Those with a family history of sarcoidosis or known genetic susceptibility may benefit from minimizing dust and particulate inhalation, avoiding unpiped water, and using pasteurized dairy products.
• Ophthalmologic surveillance after diagnosis: Silent uveitis is a treatable cause of permanent vision loss. Regular slit-lamp examination prevents this complication.
• Cardiac screening after diagnosis: Routine ECG and cardiac MRI or PET screening after a sarcoidosis diagnosis can detect cardiac involvement before it causes sudden cardiac death—an interval during which treatment may prevent an irreversible outcome.
• Vitamin D supplementation with caution: Because sarcoidosis granulomas produce calcitriol in an unregulated way, vitamin D supplements may worsen hypercalcemia. Serum calcium must be checked before any vitamin D supplementation is started or continued in sarcoidosis patients.
• Bone density monitoring: Patients on chronic corticosteroid therapy require dual-energy X-ray absorptiometry (DEXA) scanning to monitor for glucocorticoid-induced osteoporosis.

The hallmark radiological finding of sarcoidosis is bilateral hilar lymphadenopathy—enlargement of the lymph nodes at the roots of both lungs, visible on chest X-ray—often accompanied by systemic constitutional symptoms. However, sarcoidosis is a great imitator: approximately half of all patients are completely asymptomatic at diagnosis, with the disease found incidentally on imaging obtained for an entirely different purpose. When symptoms are present, they depend entirely on which organs the granulomas have formed in.

• Fatigue is the most prevalent symptom overall, affecting 50–70% of patients. It is a major driver of reduced quality of life that occurs independently of which organs are involved and often persists even when imaging improves. It is frequently underrecognized and undertreated.
• Brain fog and cognitive impairment affects approximately 35% of sarcoidosis patients; associated with small fiber neuropathy (damage to the fine sensory nerve fibers throughout the body).
• Weight loss and decreased appetite
• Low-grade fever that stays typically below 38.5 degrees Celsius. A higher fever should raise suspicion for an infectious alternative diagnosis.
• Night sweats and general malaise

• Persistent dry cough: 27–53% of patients
• Shortness of breath (dyspnea): 18–51%; chronic breathlessness is most common in advanced fibrotic disease
• Chest pain or tightness: 9–23%
• Wheezing: less common; suggests involvement of the airways (endobronchial disease) rather than the lung tissue
• Coughing up blood (hemoptysis): rare; may indicate a fungal complication called a mycetoma developing in a scarred cavity

• Erythema nodosum: tender, firm, red-purple bumps most commonly over the shins. This is the most common nonspecific skin finding and a marker of acute, self-limiting disease. It is a key feature of Löfgren syndrome.
• Lupus pernio: —firm, smooth, violaceous (purple-red) plaques on the nose, cheeks, lips, and earlobes. This is the skin finding most strongly associated with chronic, treatment-resistant sarcoidosis, sinonasal involvement, and bone disease. It disproportionately affects African American women and should prompt evaluation for systemic chronic disease.
• Papules, plaques, and subcutaneous nodules: present on the trunk and extremities
• Scar infiltration: Granulomas can form within old surgical scars, injuries, or tattoo sites. When a scar suddenly becomes raised, firm, and inflamed, sarcoidosis should be considered.

• Eye pain, redness, and intense light sensitivity: from anterior uveitis, the most common ocular form
• Blurred vision: from posterior uveitis or panuveitis affecting the back of the eye
• Dry eyes: from lacrimal gland infiltration by granulomas, affecting 15–31% of those with ocular sarcoidosis
• Visual loss: occurs in 2.4–10% of patients with sarcoid uveitis; the leading cause is cystoid macular edema—fluid accumulation in the central retina
• Double vision or drooping eyelid: from orbital or cranial nerve involvement

• Palpitations and syncope (fainting): from ventricular arrhythmias or AV block, where the electrical signal between the upper and lower chambers of the heart is slowed or blocked
• Shortness of breath disproportionate to the degree of lung disease: from cardiomyopathy (weakened heart muscle) caused by granulomatous infiltration
• Leg swelling (peripheral edema): from heart failure
• Sudden cardiac death: may be the very first manifestation of cardiac sarcoidosis, underscoring the importance of routine cardiac screening in all diagnosed patients

• Facial drooping or weakness: cranial nerve VII (facial nerve) palsy; the most common neurological manifestation. Occurs in sarcoidosis with enough frequency that Lyme disease must always be ruled out as an alternative cause.
• Headache: 32% of neurosarcoidosis patients
• Peripheral numbness, burning pain, and tingling: small fiber neuropathy affecting 40–80% of sarcoidosis patients overall, often causing chronic discomfort that is disproportionate to other measurable disease parameters
• Seizures, cognitive decline, and psychiatric symptoms: from direct granulomatous involvement of the brain
• Neck stiffness, light sensitivity, and fever: from aseptic meningitis

• Right upper quadrant abdominal pain and itching: hepatic sarcoidosis in 5–15%
• Parotid gland enlargement: swelling of the large salivary glands in front of and below the ears; a component of Heerfordt’s syndrome; can cause dry mouth
• Kidney stones: 10–14% of sarcoidosis patients; from excess calcium in the urine
• Excessive thirst and urination: from elevated blood calcium (hypercalcemia)
• Bilateral ankle swelling and joint pain: the arthropathy of Löfgren syndrome; also a feature of chronic sarcoid arthritis

In young adults (ages 20 to 40), sarcoidosis most commonly presents as Löfgren syndrome in European patients—with the rapid onset of ankle swelling, shin nodules, bilateral hilar lymphadenopathy, and constitutional symptoms—or as incidental bilateral hilar lymphadenopathy found on imaging. This age group has the best prognosis and the highest spontaneous remission rate.

In adults over 40 at presentation, prognosis is less favorable. Lupus pernio, chronic uveitis, cardiac involvement, and neurological disease are all more common. A chronic disease course requiring prolonged treatment is significantly more likely than in younger patients.

In women over 50, a second incidence peak occurs, possibly related to hormonal changes after menopause. Pulmonary disease in this group is often discovered on imaging without prominent symptoms.

In African American patients at any age, the disease is more likely to be multisystem, more likely to include lupus pernio, chronic uveitis, liver and bone marrow involvement, and cardiac and neurological disease. African American patients are more likely to require prolonged treatment and face substantially higher disease-related mortality—a disparity that demands equity-centered clinical attention.

Sarcoidosis is typically diagnosed by a pulmonologist, internist, or specialist rheumatologist. Diagnosis is challenging—often delayed by months to years—because no single definitive test exists. Three criteria must be met for a definitive diagnosis: a compatible clinical or radiological picture; histological confirmation of non-necrotizing granulomatous inflammation in at least one tissue; and exclusion of other granulomatous diseases, particularly tuberculosis, fungal infections, berylliosis, hypersensitivity pneumonitis, and Crohn’s disease. Three clinical presentations are considered pathognomonic—meaning they are specific enough to confirm sarcoidosis without a tissue biopsy: Löfgren’s syndrome, lupus pernio, and Heerfordt’s syndrome.

• Serum angiotensin-converting enzyme (SACE): elevated in approximately 60% of active sarcoidosis cases, produced by macrophages inside granulomas. It reflects the total granuloma burden across the body and is useful for monitoring treatment response over time, but it is not specific enough for primary diagnosis—it can be elevated in tuberculosis, liver disease, and other conditions. A negative SACE does not rule out sarcoidosis.
• Serum calcium and 24-hour urine calcium: hypercalcemia in 6–18% and hypercalciuria in 20–40%; results from unregulated calcitriol production by granuloma macrophages. More sensitive than serum calcium alone; used for renal risk stratification.
• Soluble IL-2 receptor (sIL-2R): This is a T-cell activation marker elevated in active sarcoidosis with better specificity than SACE; emerging as a monitoring biomarker.
• Complete blood count (CBC): This may show lymphopenia, anemia, or leukopenia in cases with bone marrow involvement.
• Liver function tests: Alkaline phosphatase is the most consistently elevated marker in hepatic sarcoidosis; elevated in a substantial proportion of patients even without symptomatic liver disease.
• Serum calcitriol (1,25-dihydroxyvitamin D): This is elevated out of proportion to 25-OH vitamin D; confirms the ectopic calcitriol production mechanism of hypercalcemia.
• Tuberculin skin test (TST/Mantoux): Most sarcoidosis patients show anergy (a negative or absent reaction despite immune system activation) because the disease diverts immune activity toward Th1 responses within granulomas, suppressing skin test reactivity. This anergy pattern helps differentiate sarcoidosis from active TB.
• QuantiFERON®-TB Gold (interferon gamma release assay—IGRA blood test): This test is mandatory before initiating any anti-TNF biologic therapy to rule out latent tuberculosis, which can reactivate under immunosuppression.

• Chest X-ray: first-line imaging; classifies pulmonary stage and identifies bilateral hilar lymphadenopathy. Eggshell calcifications of lymph nodes may be seen in chronic disease.
• High-resolution CT of the chest (HRCT): the gold standard for characterizing pulmonary sarcoidosis. Detects characteristic perilymphatic micronodules 2 to 5 mm in diameter distributed along bronchovascular bundles, interlobular septa, and the subpleural lung surface. Two highly specific HRCT patterns are the “galaxy sign” (a large central nodule surrounded by smaller satellite nodules) and the “cluster of black pearls sign”—both have negative and positive predictive values above 90% for sarcoidosis.
• 18F-FDG PET-CT: highly sensitive for detecting metabolically active granulomatous inflammation in any organ throughout the body. Guides biopsy targeting by identifying the most accessible and most active tissue. Detects cardiac, neurological, and extrathoracic involvement that would otherwise be missed. Also identifies bone sarcoidosis in approximately 14% of patients.
• Cardiac MRI: the standard of care for evaluating suspected cardiac sarcoidosis. Detects myocardial edema (active inflammation) and late gadolinium enhancement—a marker of fibrosis or scarring—and is superior to echocardiography for characterizing heart muscle tissue.
• MRI of brain and spine: This is for any neurological symptoms; detects leptomeningeal enhancement, cranial nerve involvement, pituitary infiltration, intraparenchymal granulomas, and spinal cord involvement.
• Echocardiography: This is used as initial cardiac screening; detects wall motion abnormalities, ventricular dysfunction, and structural changes, though it is less sensitive than cardiac MRI for tissue characterization.
• Gallium-67 scintigraphy: historically used to detect active granulomatous inflammation; now largely superseded by FDG-PET. The “panda sign” (bilateral parotid and lacrimal gland uptake) and “lambda sign” (right paratracheal and bilateral hilar uptake) on gallium scanning are highly specific patterns for sarcoidosis.

Demonstrating non-necrotizing (non-caseating) granulomas on tissue biopsy is the cornerstone of definitive diagnosis. Non-caseating means there is no central zone of cheese-like tissue death—the finding that distinguishes sarcoid granulomas from those of tuberculosis and fungal infections. The preferred biopsy site is whichever tissue is most accessible and most likely to yield a sample. Skin biopsy is preferred first when lupus pernio or other specific skin lesions are present—it is minimally invasive and has a high diagnostic yield. When pulmonary or mediastinal disease is the primary finding, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the preferred first-line procedure—a minimally invasive bronchoscopic technique that samples enlarged lymph nodes in the mediastinum and lung roots without surgery, replacing mediastinoscopy in most cases. Transbronchial lung biopsy via bronchoscope samples lung tissue directly and is combined with EBUS for the highest combined yield in parenchymal disease. Bronchoalveolar lavage—washing a small area of lung with saline and analyzing the returned fluid—shows lymphocytosis in 80% of sarcoidosis cases; a CD4 to CD8 T-cell ratio above 3.5 has a specificity of 93–96% for sarcoidosis when present. Peripheral lymph node biopsy is used when accessible nodes are enlarged. Conjunctival biopsy is performed in some uveitis cases and provides a diagnosis in approximately 25% even without visible conjunctival involvement. Endomyocardial biopsy is used for suspected isolated cardiac sarcoidosis when noninvasive imaging is inconclusive, though its sensitivity is only approximately 25% due to the patchy distribution of cardiac granulomas. Video-assisted thoracoscopic surgery (VATS) is reserved for cases where less invasive sampling has not achieved a diagnosis and tissue confirmation is essential.

Spirometry measures forced vital capacity (FVC)—the hallmark finding in sarcoidosis is a restrictive pattern, with reduced FVC but a preserved or elevated forced expiratory volume in one second (FEV1)/FVC ratio. The DLCO measures the lungs’ gas transfer efficiency and is reduced when fibrosis or vascular involvement is present; its reduction correlates with overall disease extent. The six-minute walk test measures functional exercise capacity and correlates with quality of life. Cardiopulmonary exercise testing (CPET) can identify the mechanism of breathlessness when spirometry and DLCO are normal. A composite physiologic index above 40 on testing predicts increased mortality risk.

All newly diagnosed sarcoidosis patients have a baseline ECG. High-degree AV block—when the electrical signal between heart chambers is severely disrupted—and ventricular arrhythmias are the characteristic cardiac findings. A 24-hour Holter monitor extends arrhythmia detection over time. Electrophysiology study (EPS) evaluates the ventricular arrhythmia substrate in patients with known or suspected cardiac involvement. Right heart catheterization definitively diagnoses pulmonary arterial hypertension—a serious complication of advanced pulmonary and cardiac sarcoidosis.

Sarcoidosis is not curable, but it is often manageable—and for many patients, it resolves on its own without any treatment at all. Not every patient with sarcoidosis needs medication. The decision to treat is based on four criteria: significant impairment of organ function; risk of permanent organ damage without intervention; seriously impaired quality of life; or life-threatening involvement of the heart or nervous system. For asymptomatic Scadding stage I or II disease with preserved pulmonary function, watchful waiting for 3 to 12 months is the endorsed approach—spontaneous remission rates for stage I are 55–90%, and for stage II 4070%. When treatment is initiated, it follows a recognized three-tier stepped approach individualized to the organ involved, disease severity, comorbidities, and patient tolerance. An important note: no medication is specifically U.S. Food and Drug Administration (FDA)-approved for sarcoidosis; all pharmacological treatments described here are used off-label. Multidisciplinary care is mandatory for complex disease—pulmonology, cardiology, neurology, ophthalmology, rheumatology, dermatology, and nephrology are all involved as appropriate.

Oral corticosteroids are the cornerstone of sarcoidosis pharmacotherapy. They are highly effective at suppressing granulomatous inflammation and reversing organ dysfunction. The standard first-line regimen is oral prednisone or prednisolone at 0.5 to 0.75 mg/kg/day for four weeks, then tapered by 10 mg every four weeks to a maintenance dose of 5 to 10 mg per day for a total course of at least six months. The long-term side effects of corticosteroids—weight gain, elevated blood sugar, osteoporosis, cataracts, elevated blood pressure, adrenal suppression, and mood changes—require active monitoring and management throughout the treatment course. High-dose intravenous methylprednisolone pulse therapy is reserved for severe acute manifestations: acute neurosarcoidosis, severe cardiac involvement, or sight-threatening uveitis. Inhaled budesonide has limited evidence for mild pulmonary stage I to II disease with minimal systemic involvement, as it avoids systemic side effects at the cost of lower overall efficacy.

When corticosteroids cannot be tapered to an acceptable dose (below 10 mg per day), when corticosteroid toxicity is intolerable, or when disease persists on corticosteroids beyond six months, a second-line steroid-sparing immunosuppressive agent is added. Methotrexate (10 to 15 mg per week orally or by subcutaneous injection, with mandatory daily folic acid supplementation) is the most commonly used antimetabolite for sarcoidosis; CBC and liver function tests are monitored every three months. Azathioprine (50 to 200 mg per day orally) is the standard alternative to methotrexate; thiopurine methyltransferase (TPMT) genotype testing before initiation identifies patients at risk of severe myelosuppression. Hydroxychloroquine (Plaquenil®, 200 to 400 mg per day) is preferred for skin involvement, joint disease, and hypercalcemia-related sarcoidosis; it has the most favorable safety profile of the second-line agents and requires only an annual ophthalmology examination for retinal monitoring. Mycophenolate mofetil (1,000 to 3,000 mg per day) is increasingly used for pulmonary, ocular, and neurosarcoidosis. Leflunomide (20 mg per day) is an alternative to methotrexate with a long half-life requiring monitoring of liver function.

When disease persists despite corticosteroids combined with a second-line agent—particularly in neurosarcoidosis, cardiac sarcoidosis, refractory pulmonary or cutaneous or ocular disease, and chronic multisystem granulomatous disease—biologic therapies targeting specific immune pathways are used, all off-label for sarcoidosis. Mandatory tuberculosis screening (interferon-gamma release assay—IGRA blood test) is required before initiating any anti-TNF agent because these drugs can reactivate latent tuberculosis. Infliximab (Remicade®), a chimeric anti-TNF-alpha monoclonal antibody given by intravenous infusion, has the most clinical evidence in sarcoidosis of any biologic and is the most commonly used. It is effective for refractory pulmonary, chronic cutaneous, ocular, and neurosarcoidosis. Adalimumab (Humira®), a fully human anti-TNF-alpha antibody given by subcutaneous injection every two weeks, is a comparable alternative with the practical advantage of at-home administration. Rituximab (Rituxan®), which depletes B-cells by targeting the CD20 protein, is used in selected refractory cases of pulmonary, cutaneous, and cardiac sarcoidosis. Tocilizumab (Actemra®), an IL-6 receptor inhibitor, is used in selected refractory cases that have failed both corticosteroids and anti-TNF agents. Janus kinase (JAK) inhibitors—ruxolitinib and tofacitinib, taken orally—have emerging evidence specifically in refractory cutaneous sarcoidosis, including lupus pernio. Ustekinumab, which targets IL-12 and IL-23, was evaluated in a randomized controlled trial for pulmonary sarcoidosis but did not meet its primary efficacy endpoint.

Cardiac sarcoidosis is treated with corticosteroids (prednisone 30 to 40 mg per day) as first-line, with methotrexate or azathioprine as steroid-sparing agents. Ventricular arrhythmias are managed with anti-arrhythmic medications. Complete AV block requires a permanent pacemaker. Significant ventricular arrhythmias or reduced ejection fraction below 35% requires an implantable cardioverter-defibrillator (ICD) to prevent sudden cardiac death. Standard heart failure medications—angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and diuretics—are used for cardiomyopathy. End-stage cardiac sarcoidosis refractory to all medical management may require heart transplantation.

Neurosarcoidosis is treated with high-dose intravenous methylprednisolone pulse therapy transitioning to oral prednisone, with methotrexate or mycophenolate mofetil as steroid-sparing agents. Infliximab is the preferred biologic for refractory neurosarcoidosis. Anti-epileptic drugs are used for seizures; diuretics and acetazolamide reduce elevated intracranial pressure when present.

Ocular sarcoidosis is treated with topical corticosteroid eye drops (prednisolone acetate) plus cycloplegic drops for anterior uveitis. Periocular or intravitreal triamcinolone acetonide injections treat refractory posterior uveitis. Systemic prednisone is required for bilateral, posterior, or panuveitis. Methotrexate or mycophenolate provides steroid-sparing for chronic uveitis; infliximab or adalimumab is reserved for refractory ocular disease.

Sarcoidosis-related hypercalcemia is treated with corticosteroids as first-line—they suppress the unregulated calcitriol production by granuloma macrophages. Patients must restrict calcium and vitamin D intake, stay well hydrated, and avoid prolonged sun exposure (which drives vitamin D production). Hydroxychloroquine is an effective steroid-sparing option for mild hypercalcemia.

Cutaneous sarcoidosis without disfigurement is treated with topical corticosteroids or intralesional corticosteroid injections, with hydroxychloroquine as a systemic steroid-sparing option. Refractory cutaneous disease, including lupus pernio, is treated with systemic prednisone, methotrexate, infliximab, or adalimumab; JAK inhibitors are emerging as options in this specific indication.

Pulmonary rehabilitation improves exercise capacity, breathlessness, and quality of life in patients with functional limitation from pulmonary sarcoidosis. Physical therapy manages musculoskeletal sarcoidosis, myopathy, and fatigue through graded exercise programs. Occupational therapy provides energy conservation strategies and adaptive devices for patients with severe fatigue, neuropathy, or functional impairment. Cognitive behavioral therapy (CBT) addresses sarcoidosis-associated depression, anxiety, cognitive impairment, and the chronic pain of small fiber neuropathy. Fatigue management programs using validated tools like the Fatigue Assessment Scale, pacing strategies, and behavioral activation techniques have demonstrated benefit. Supplemental oxygen is used for patients with pulmonary hypertension or advanced fibrosis causing resting hypoxemia.

Lung transplantation is performed for end-stage pulmonary sarcoidosis (Scadding stage IV fibrosis) with advanced respiratory failure; five-year survival is approximately 50%, and there is a risk of sarcoidosis recurrence in the transplanted lung in approximately 35% of cases. Heart transplantation is available for end-stage cardiac sarcoidosis refractory to medical management. Permanent pacemaker implantation is required for high-degree (second or third-degree) AV block from cardiac sarcoidosis. An implantable cardioverter-defibrillator (ICD) is placed for ventricular arrhythmias or reduced ejection fraction below 35%. Electrophysiology study with catheter ablation is used for recurrent ventricular tachycardia as an adjunct to ICD therapy. VATS and mediastinoscopy are reserved for diagnostic biopsy when less invasive approaches have not yielded a diagnosis. Arthrocentesis, synovial biopsy, and joint replacement are orthopedic options for severe sarcoid arthropathy.

Sarcoidosis affects people in dramatically different ways, and the impact on daily life depends entirely on which organs are involved, how severe the disease is, and whether it follows an acute self-limiting course or becomes chronic. The majority of patients—particularly those with Löfgren syndrome or early-stage pulmonary disease—recover fully within two to three years, often without any treatment at all. For others, sarcoidosis becomes a long-term condition requiring ongoing management, medication adjustments, and regular specialist follow-up. Even patients whose imaging and laboratory values have improved often continue experiencing significant fatigue, chronic pain, cognitive difficulties, and small fiber neuropathy—symptoms that are frequently underrecognized and can profoundly affect work, relationships, and quality of life. It is important for both patients and clinicians to acknowledge these invisible burdens as real and meaningful, not as signs that the disease is imagined or exaggerated.

African American patients and those diagnosed after age 40 with multisystem involvement face a greater likelihood of a chronic disease course and should be followed closely by a multidisciplinary care team experienced in sarcoidosis. The racial mortality disparity in sarcoidosis—a death rate more than twelve times higher in Black Americans than in white Americans—reflects both biological differences in disease phenotype and broader structural inequities in healthcare access and quality. Patients, families, and clinicians should be aware of this disparity as both a personal health reality and a call for advocacy.

Treatment can suppress granulomatous inflammation and prevent organ damage, but in advanced cases—particularly stage IV pulmonary fibrosis and cardiac involvement—damage already sustained may be irreversible. Setting realistic expectations, making the most of the treatment window before fibrosis becomes established, and building a care team that includes the right specialists early in the disease course are among the most important steps a patient with sarcoidosis can take. The Foundation for Sarcoidosis Research (FSR) (stopsarcoidosis.org) provides patient education resources, clinical trial information, and connections to the sarcoidosis patient community.

To further your understanding of your diagnosis and to contribute to cutting-edge research, consider participating in a clinical trial so clinicians and scientists can learn more about causes, symptoms, treatment, and prevention of sarcoidosis and related disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease.

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them.

To learn more about clinical trials and find studies that may be right for you, visit National Institutes of Health (NIH) Clinical Research Trials and You and ClinicalTrials.gov to search active studies by condition, location, and age group.